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Objective: This study compared adherence and persistence of three branded antidepressants: 
the serotonin and norepinephrine reuptake inhibitors (SNRIs) duloxetine and venlafaxine XR, 
and the selective serotonin reuptake inhibitor (SSRI) escitalopram; and generic selective SSRIs, 
and examined demographic and clinical predictors of adherence and persistence in patients with 
major depressive disorder in usual care settings.
Method: A total of 44,026 patients (18 to 64 years) from a large commercial administrative 
claims database were classified as initiators of duloxetine (n = 7,567), venlafaxine XR (n = 6,106), 
escitalopram (n = 10,239), or generic SSRIs (n = 20,114) during 2006. Adherence was defined as 
the medication possession ratio of $0.8 and persistence as the length of therapy without exceeding 
a 15-day gap. Pairwise comparisons from multivariate logistic regression and Cox proportional 
hazards models were performed to examine predictors of adherence and persistence.
Results: Adherence rate after one year was significantly higher in duloxetine recipients (38.1%) 
than patients treated with venlafaxine XR (34.0%), escitalopram (25.4%), or generic SSRIs 
(25.5%) (all P , 0.01). Duloxetine recipients stayed on medication longer (158.5 days) than those 
receiving venlafaxine XR (149.6 days), escitalopram (129.1 days), or generic SSRIs (130.2 days) 
(all P , 0.001). Compared with patients treated with escitalopram or generic SSRIs,   venlafaxine 
XR recipients had better adherence and longer persistence (P , 0.001). In addition, being aged 
36 years or more, hypersomnia, anxiety disorders, and prior use of antidepressants were associ-
ated with increased adherence and persistence, while the opposite was true for comorbid chronic 
pain conditions, alcohol and drug dependence, and prior use of amphetamine.
Conclusion: Compared with SSRIs, the SNRIs appear to have better adherence and persistence. 
Among SNRIs, duloxetine had statistically significantly better adherence and persistence than 
venlafaxine XR, though differences were relatively small and further research is needed to assess 
whether these translate into clinically and economically meaningful outcomes.   Adherence and 
persistence with antidepressant therapy were associated with age, multiple comorbid conditions, 
and prior use of medications.
Keywords: treatment adherence, length of therapy, antidepressants, major depression, 
  retrospective analysis
Introduction
Major depressive disorder (MDD) is among the most prevalent and costly   psychiatric 
disorders.1–3 Antidepressants are the mainstay treatment of MDD and optimal 
  antidepressant treatment includes the selection of the right medication and delivery 
at a fully therapeutic dose for a sufficient treatment duration.4,5ClinicoEconomics and Outcomes Research 2011:3 submit your manuscript | www.dovepress.com
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However, antidepressant nonadherence remains a 
  challenging problem in the treatment of depression. Treat-
ment is often accompanied by premature discontinuation 
and switching of antidepressant medications,8 which may 
be associated with likelihood of relapse and higher health-
care costs.9,10 Research demonstrates that 28% of patients 
  discontinue use of their antidepressant medication within the 
first month, and by three months, at least 40% have discontin-
ued use.11 Approximately 16% of patients remain on therapy 
for more than 90 days without evidence of therapy changes, 
titration in dose, or being only partially compliant.12 The early 
discontinuation of antidepressant medication is statistically 
associated with a 77% increase in the risk of relapse.10
In many cases, poor adherence or discontinuation of 
therapy was thought to be an effect related primarily to 
adverse events or lack of therapeutic response.13 However, 
there are multiple factors that may put patients at risk for poor 
adherence or discontinuation. Many patient-related, disease-
related, medication-related, and physician-related factors, 
along with the health care system and costs may influence a 
patient’s adherence to medication therapy.13–21
The second generation of antidepressants, such as selec-
tive serotonin (5-HT) reuptake inhibitors (SSRIs) and sero-
tonin and norepinephrine (NE) reuptake inhibitors (SNRIs), 
are commonly used in the treatment of depression. Although 
findings are inconsistent, some studies suggest that SNRIs 
that modulate both 5-HT and NE activity may be more 
effective than SSRIs for patients with more severe major 
depression.22,23 Although some antidepressants are grouped 
into the same class, they may have different pharmacological 
and clinical profiles.24–27
At the time of the analyses, three branded antidepressants 
commonly used in the treatment of depression in the United 
States were two SNRIs: duloxetine (DLX) and venlafaxine 
(VLX) and one SSRI: escitalopram (ECP). Recent research 
showed that DLX-treated patients had more comorbid con-
ditions, especially chronic pain-related diseases, and that 
ECP-treated patients were very similar to generic SSRI 
(GSSRI)-treated patients in demographic characteristics and 
comorbid conditions.28 Branded antidepressants are usually 
more expensive than GSSRIs. However, little is known about 
treatment patterns and the clinical and economic consequences 
of patients treated with branded antidepressants compared 
with GSSRIs. The objectives of this study were to examine 
treatment adherence and persistence with the three branded 
antidepressants DLX, VLX, and ECP, and GSSRIs in the 
treatment of major depression, and to examine demographical 
and clinical predictors of adherence and persistence with 
antidepressant therapy in the usual clinical setting.
Patients and Methods
Data source and sample selection
This retrospective analysis of claims data employed medical, 
pharmacy, and enrollment information from the Thomson 
Reuters MarketScan Commercial Claims and Encounters 
Databases, which includes de-identified administrative 
claims databases of employees, spouses, and dependents with 
employer-sponsored commercial insurance. Inpatient and out-
patient medical and pharmacy claims are linked to enrollment 
data for a variety of plan types. This database captures the 
annual health care information of approximately 20 million 
individuals, including inpatient and outpatient medical 
claims linked to pharmacy and enrollment data for a variety 
of health insurance plan types. Each medical claim includes 
at least one International Classification of Diseases (ICD), 
9th Edition, Clinical Modification (ICD-9-CM) diagnostic 
code to describe the patient’s clinical condition. All pertinent 
patient information in the database was encrypted and de-
identified. The MarketScan database is publicly available as 
a   fee-for-service database and has been used for a number of 
previous retrospective and prospective analysis projects.29,30
Patients were included in the study if they had a first prescrip-
tion fill for DLX, VLX, ECP, or a GSSRI in 2006, had no active 
prescriptions of the same study medication in the three months 
prior to the index date, and had one or more inpatient or outpa-
tient claims associated with a diagnosis of MDD (ICD-9-CM: 
296.2 and 296.3) one year prior to or one month after the study 
medication was initiated. Patients had to be 18 to 64 years of 
age, commercially insured, and have continuous enrollment in 
the previous and following twelve months. Patients initiated on 
more than one study medication (DLX, VLX, ECP, or GSSRIs) 
during 2006 at different times were grouped into the first medi-
cation initiation cohort while those starting on more than one 
type of study medication on the index date were excluded from 
the study. Patients were grouped into four mutually exclusive 
cohorts: DLX, VLX, ECP, or GSSRI. The study design and 
sample selection are illustrated in Figure 1.
Adherence and persistence
Medication adherence was assessed using the medication 
possession ratio (MPR), defined as the sum of the days’ 
  supply of study medication within one year after the index 
date divided by 365 days.6,7 Adherence to therapy was defined 
as an MPR $ 0.8. Medication persistence was defined as ClinicoEconomics and Outcomes Research 2011:3 submit your manuscript | www.dovepress.com
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the number of days from the index date to the earliest of the 
  ending date of the last prescription, the date of the first gap 
of more than 15 days between prescriptions, or the end of the 
study period of twelve months, whichever came first.6,7
Pretreatment variables
Pretreatment variables included demographic characteristics 
(age, gender, geographic region of residence, and health 
plan type), comorbidities, and prior use of medications. 
  Comorbidities included 20 chronic pain conditions, sleep 
disorders, psychiatric disorders, and other physical disorders 
(see Table 1 for detail) that are associated with safety,   efficacy, 
or adherence of antidepressant treatment.28,31–37 Prior use of 
medications included specified therapeutic classes, as well 
as selected individual drugs known to be used in treating 
depression, psychosis, bipolar disorders, anxiety, sleep 
  disorders, or chronic pain that are known to be associated with 
physicians’ choice of antidepressants.4,33,38,39 All medications 
were identified on the basis of National Drug Codes.
statistical analyses
Summary statistics were presented as means and standard 
deviations for continuous variables and as percentages for 
  categorical variables. Demographic characteristics at the 
index date of study medication initiation, comorbid condi-
tions, and medications used in the preindex period (one 
year prior to index date) were compared between the four 
medication cohorts. Chi-square tests were performed for 
comparisons of categorical variables and analysis of variance 
for comparisons of continuous variables. Kaplan–Meier sur-
vival curves were produced to show times to discontinuation 
of the four study medication cohorts.
Pairwise comparisons were conducted to examine 
the differences in adherence and persistence between the 
four study medication cohorts, adjusting for demographic 
variables, comorbid conditions, and prior medication use. 
The Tukey–Kramer method was used to adjust for multiple 
comparisons.
A multivariate stepwise logistic regression and Cox 
proportional hazards regression analyses were conducted to 
determine variables that independently predicted adherence 
and time to discontinuation (persistence) in the study, adjust-
ing for all the variables in the model. Independent variables 
for the multivariate stepwise logistic regression included 
study medications, demographics, comorbid disorders, and 
concomitant medications in the pre-study period. Odds ratios 
Patients aged 18–64 years and treated with
duloxetine, venlafaxine XR, escitalopram, or
generic SSRI
1/1/06–12/21/06
N = 1,787,135
Patients without use of study drug in the prior
3 months
N = 654,011
Patients with ¥1 outpatient or inpatient MDD
claim in the prior 12 months or in the post
30 days
N = 80,806
Patients continuously eligible for a health care
plan for 12 months prior and post index date
N = 44,026
Duloxetine-
treated patients
N = 7,567
Venlafaxine XR-
treated patients
N = 6,106
Escitalopram-
treated patients
N = 10,239
Generic SSRI-
treated patients
N = 20,114
Figure 1 summary of study design and sample selection.
Abbreviations: n, number of patients; MDD, major depressive disorder; ssRi, selective serotonin reuptake inhibitor.ClinicoEconomics and Outcomes Research 2011:3 submit your manuscript | www.dovepress.com
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Table 1 Comorbid conditions and iCD-9-CM diagnosis codes
Diagnosis code(s)
Pain conditions
headaches 307.81, 346.xx, 784.0x
Rheumatoid arthritis 714.xx
Osteoarthritis 
(Osteoarthrosis and  
allied disorders)
715.xx
Low back pain 721.3x, 722.10, 722.32, 722.52, 722.93, 724.02
724.2x–724.7x, 738.5x, 739.3x, 739.4x,  
846, 847.2x
Fibromyalgia 729.1x
neuropathic pain  250.6x, 357.2x, 350.1x, 353.6x, 053.1x
Psychiatric and  
sleep disorders
Dysthymic disorder 300.4x
Anxiety disorders 300.0x, 300.23, 308.xx
Alcohol abuse/
dependence
305.0x, 303.xx
Drug dependence 304.xx
Bipolar disorders 296.0, 296.1, 296.4–7, 296.80, 296.81, 296.89
Organic psychosis 290.xx–294.xx
insomnia 780.51, 780.52
hypersomnia 780.53, 780.54
Obstructive sleep apnea 327.23
Other diseases
Diabetes mellitus 250.xx (except 250.6)
hypertensive diseases 401.xx–405.xx
hepatic diseases 570.xx–573.xx
Renal diseases 580.xx–591.xx, 592.0x, 593.0x–593.2x,  
593.81, 593.9x
Abbreviations: ICD-9-CM, International Classification of Diseases, 9th Edition, 
Clinical Modification; MDD, major depressive disorder.
(ORs) and 95% confidence intervals (CI) from the logistic 
regression model were used to examine the associations of 
predicting variables with adherence. The larger the odds 
ratio was, the higher the likelihood of adherence to the 
study medication. Hazard ratios (HRs) and 95% confidence 
intervals from the Cox proportional hazards model were used 
to examine associations of predicting variables with time 
to discontinuation of medication. The smaller the hazard 
ratio was, the less the likelihood of discontinuation of the 
medication.
Sensitivity analyses were conducted to compare group 
differences in adherence and persistence. First, adherence and 
persistence in the six months after initiation were computed. 
Second, persistence was estimated using an alternative 
  allowable 30-day gap. Third, 17-ICD classes of systemic 
diseases as comorbid conditions were used instead of selected 
diseases for multivariate logistic and Cox proportional   hazards 
regression modeling. All statistical analyses were performed 
using SAS (v 9.1; SAS institute, Inc, Cary, NC).
Results
A total of 44,026 patients with continuous enrollment in the 
health plan for twelve months prior to and post index date 
were included in the study. Demographic characteristics 
of the sample by medications are reported in Table 2. The 
sample was primarily female and had a mean age ranging 
from 43.7 to 47.2 years by medications (P , 0.0001). 
Within each medication cohort, approximately one-third 
of the sample was aged 46 to 55 years. Most of the sample 
had a Preferred Provider Organization (PPO) health plan 
which was highest in the DLX group (P , 0.0001), and 
more patients from each drug group lived in the South 
(P , 0.0001).
Figure 2 presents adherence to antidepressant therapy 
across four medications. In the six months after medication 
initiation, antidepressant adherence was highest for DLX 
(48.7%), followed by VLX (45.9%), and ECP and GSSRIs 
(37.2%). In the twelve months after medication initiation, 
adherence rate declined for all medication cohorts. DLX 
was still highest (38.1%) and ECP and GSSRIs were low-
est (25.4% and 25.5%, respectively). Pairwise comparisons 
showed that DLX had a significantly higher adherence rate 
than the three comparators and that VLX had a significantly 
higher adherence rate than ECP and GSSRIs at six months 
and twelve months (all P , 0.01).
In the twelve months after medication initiation, 
average length of therapy (persistence) was 158.5 days 
(SD = 133.9, median = 95.0) with DLX; 149.6 days 
(SD = 129.9, median = 90.0) with VLX; 129.1 days (SD = 119.8, 
median = 90) with ECP; and 130.2 days (SD = 120.7, 
median = 90.0) with GSSRIs, respectively. Pairwise com-
parisons showed that the average persistence duration was 
significantly longer in DLX-treated patients compared to 
patients treated with VLX (P , 0.001), ECP (P , 0.001), 
or GSSRIs (P , 0.001). Length of therapy was significantly 
longer in VLX-treated patients compared to patients treated 
with ECP (P , 0.001) or GSSRIs (P , 0.001). However, 
ECP and GSSRIs did not significantly differ in length of 
therapy (P . 0.05).
Figure 3 shows the Kaplan–Meier curves (time to discon-
tinuation) of different antidepressant therapies in the twelve 
months after medication initiation. In the first 30 days, about 
30% of patients discontinued their therapy across all treat-
ment groups. After 30 days, DLX and VLX appeared to be 
different from ECP and GSSRIs and after 90 days, DLX was 
less likely to be discontinued than VLX. The median time to 
discontinuation was 95 days in DLX-treated patients, 90 days ClinicoEconomics and Outcomes Research 2011:3 submit your manuscript | www.dovepress.com
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Table 2 Demographic characteristics of patients initiated on duloxetine, venlafaxine XR, escitalopram, or generic ssRis
Duloxetine 
(n = 7,567)
Venlafaxine XR 
(n = 6,106)
Escitalopram 
(n = 10,239)
Generic SSRIs 
(n = 20,114)
P-values
Female gender (%) 75.1 71.5 69.7 70.5 ,0.0001
Age group (years) (%)
18–25 4.8 9.1 11.5 11.1 ,0.0001
26–35 9.3 12.5 13.8 13.9
36–45 23.7 23.8 24.9 24.5
46–55 38.4 33.1 31.1 31.1
56–64 23.9 21.4 18.7 19.4
Mean, years (sD) 47.2 (10.6) 45.1 (11.9) 43.7 (12.4) 43.8 (12.4) ,0.0001
Health plan type (%)
Comprehensive 11.8 10.1 9.6 10.1 ,0.0001
hMO 18.6 21.3 19.3 28.4
POs 11.5 12.9 12.7 12.6
PPO 56.0 53.3 55.8 46.8
Other 2.1 2.4 2.7 2.1
Region of residence (%)
northeast 8.8 10.1 10.2 10.9 ,0.0001
north central 30.7 30.7 31.7 29.8
south 40.8 35.9 36.8 31.2
West 19.4 22.8 20.9 27.6
Unknown 0.3 0.5 0.4 0.5
Note: P-value based on chi-square test for categorical variable or F-test for continuous variable.
Abbreviations: hMO, health maintenance organization; n, number of patients; POs, point of service; PPO, preferred provider organization; sD, standard deviation;   
ssRi, selective serotonin reuptake inhibitor.
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Figure 2 Antidepressant adherence (%) in patients with major depressive disorder 
in the six months and twelve months after medication initiation.
in VLX-treated patients, 90 days in ECP-treated patients, and 
90 days in GSSRI-treated patients. Altogether, DLX-treated 
patients were less likely to discontinue than patients treated 
with VLX, ECP, or GSSRIs (P , 0.001).
Table 3 presents the multivariate stepwise logistic and 
Cox proportional hazards regression results for adherence and 
discontinuation with medication therapy, respectively. ORs 
and HRs were used to describe the strength of the associations 
between significant variables and adherence and discontinu-
ation in the final model. Compared with GSSRIs, patients 
treated with DLX were more likely to be adherent (OR = 1.66, 
CI: 1.57–1.76), followed by VLX (OR = 1.43, CI: 1.34–1.52). 
The OR for ECP was 0.99, indicating ECP and GSSRIs were 
very similar in adherence after adjustment for demograph-
ics, comorbid conditions and prior use of medications. Also, 
patients were more likely to remain adherent if they were 
older (36 years and above), had   comorbid hypersomnia, and 
had used medications including VLX, ECP, other antide-
pressants, anticonvulsants, and antimigraine medications in 
the prior year (Table 3). However, patients were less likely 
to be adherent if they had comorbid chronic pain diseases 
(headaches, low back pain, and fibromyalgia), alcohol and 
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Table 3 Multivariate logistic regression and Cox proportional hazards regression: predictors of adherence or persistence with 
antidepressant therapy
Adherence Discontinuation
OR 95% CI HR 95% CI
Antidepressant
generic ssRis 1.00 1.00
Escitalopram 0.99 0.94–1.05 1.02 0.997–1.05
Venlafaxine XR 1.43 1.34–1.52 0.85 0.83–0.88
Duloxetine 1.66 1.57–1.76 0.81 0.78–0.83
Female gender 1.05 1.00–1.10
Age (years)
18–35 1.00 1.00
36–45 1.47 1.38–1.57 0.85 0.82–0.87
46–55 1.65 1.55–1.75 0.80 0.78–0.82
56–64 2.06 1.93–2.21 0.72 0.70–0.74
Health plan type
PPO  1.00 1.00
Comprehensive  0.91 0.84–0.98 1.05 1.01–1.09
hMO 0.90 0.85–0.95 1.02 0.99–1.05
POs  0.99 0.93–1.06 0.99 0.92–1.06
Other  1.03 0.89–1.18 0.95 0.92–0.99
Geographic region of residence
north central 1.00 1.00
northeast  1.09 1.01–1.18 0.95 0.92–0.99
south 0.91 0.86–0.96 1.06 1.04–1.09
West 1.05 0.98–1.11 0.96 0.93–0.99
Comorbid diseases
headaches 0.89 0.84–0.95 1.05 1.02–1.09
Rheumatoid arthritis
Osteoarthritis
Low back pain 0.94 0.89–0.99 1.06 1.04–1.09
Fibromyalgia 0.90 0.83–0.95
neuropathic pain 
insomnia
hypersomnia 1.23 1.11–1.36 0.91 0.86–0.95
Obstructive sleep apnea
Dysthymic disorder
Anxiety disorders 0.97 0.94–0.99
Alcohol dependence 0.75 0.66–0.85 1.17 1.11–1.24
Drug dependence 0.66 0.56–0.78 1.22 1.14–1.31
schizophrenia
Bipolar disorders
Organic psychosis
Diabetes mellitus (except 250.6)
hypertensive diseases
hepatic diseases
Renal diseases
Prior medications
hypnotics
Benzodiazepines 1.04 1.01–1.06
Anxiolytics
Other ssRis 1.05 1.00–1.10
Duloxetine
Venlafaxine 1.26 1.18–1.35 0.91 0.88–0.94
Escitalopram 1.13 1.07–1.20 0.95 0.92–0.96
TCAs 1.10 1.02–1.19
MAOis
(Continued)ClinicoEconomics and Outcomes Research 2011:3 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
69
Adherence and persistence with antidepressants in major depressive disorder
Table 3 (Continued)
Adherence Discontinuation
OR 95% CI HR 95% CI
Other antidepressants 1.12 1.07–1.18 0.94 0.92–0.96
Typical antipsychotics
Atypical antipsychotics
Lithium
Amphetamine 0.87 0.78–0.98 1.11 1.05–1.17
Methylphenidate 
Modafinil 0.94 0.88–0.998
Anticonvulsants 1.11 1.05–1.18 0.95 0.92–0.98
Opioids 0.88 0.84–0.92 1.08 1.06–1.11
nsAiDs
Muscle Relaxant 0.94 0.89–0.99
Antimigraine 1.16 1.07–1.27 0.90 0.86–0.94
Notes: Odds ratio (OR) and its 95% Ci for adherence were calculated from a multivariate logistic regression model. hazard ration (hR) and its 95% Ci for discontinuation 
were calculated from the Cox proportional hazards regression model.
Abbreviations: CI, confidence interval; HMO, health maintenance organization; MAOIs, Monoamine oxidase inhibitors; NSAIDs, Nonsteroidal anti-inflammatory drugs;   
OR, odds ratio; POs, point of service; PPO, preferred provider organization; ssRi, selective serotonin reuptake inhibitor; TCAs, tricyclic antidepressants.
drug dependence, and prior use of amphetamines, opioids, 
and muscle relaxants.
As shown in Table 3, compared with GSSRIs, patients 
treated with DLX were less likely to discontinue medication 
therapy in the twelve months after initiation (HR = 0.81, 
CI: 0.78–0.83), followed by VLX (HR = 0.85, CI: 0.83–0.88). 
ECP was very similar in the likelihood of discontinuation to 
GSSRIs (HR = 1.02, CI: 1.00–1.05). Predictors associated 
with decreased likelihood of discontinuation with antide-
pressant therapy included older age (36 years and above), 
hypersomnia, anxiety disorders, and prior use of VLX, 
ECP, other antidepressants, modafinil, anticonvulsants, and 
antimigraine medications. Factors associated with increased 
likelihood of discontinuation were chronic headaches, low 
back pain, alcohol and drug dependence, and prior use of 
benzodiazepines, amphetamine, and opioids.
In sensitivity analyses the group differences in adherence 
and persistence across the four medication cohorts had no 
essential changes 1) if patients were followed for six months, 
2) if an alternative allowable 30-day gap was used to estimate 
persistence, and 3) if 17-ICD classes of systemic diseases 
were used to capture comorbid diseases instead of selected 
comorbid diseases. Similar predictors of adherence and dis-
continuation were also observed for 6-month and 12-month 
follow-ups and for an allowable 15-day and 30-day gap.
Discussion
This study examined adherence and persistence with three 
branded antidepressants (DLX, VLX, and ECP) and   GSSRIs 
in usual clinical settings. Our results showed that the 
adherence rate was 46% for VLX, 49% for DLX, and 37% 
for ECP and GSSRIs in the six months after initiation and 
declined markedly in the second six months for all antide-
pressants. Patients treated with DLX were more adherent to 
and stayed on medication longer than patients treated with 
VLX, ECP, or GSSRIs. VLX-treated patients had better 
adherence and longer persistence with therapy than patients 
treated with ECP or GSSRIs. However, ECP was similar to 
GSSRIs in adherence and persistence. In addition, multiple 
demographic and clinical pretreatment factors were associ-
ated with treatment adherence and persistence.
The adherence rate was 38.1% and 34.0% for DLX 
and VLX and approximately 25% for the SSRIs in the 
year after initiation. About 30% of patients discontinued 
their   medication within 30 days. The American Psychiatric 
Association treatment guideline recommends at least four to 
eight weeks of treatment during the acute phase followed by 
16 to 20 weeks of treatment following remission during the 
continuation phase.40 The American College of Physicians 
guideline recommends treatment for four to nine months 
after a satisfactory response in patients with a first episode 
of MDD and an even longer duration of therapy for patients 
who have had two or more episodes of depression.41 Given 
the consequence of early premature discontinuation and 
nonadherence,10,33 it is important to improve patient adher-
ence to medication therapy and give long enough therapy to 
reduce relapse and hospitalization and costs.
SNRIs (DLX and VLX) have better adherence and longer 
persistence than SSRIs including ECP. Over the 1-year study 
period, the difference in adherence between SNRIs and ClinicoEconomics and Outcomes Research 2011:3 submit your manuscript | www.dovepress.com
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SSRIs was 9% to 12% and the difference in length of therapy 
was 19 to 29 days. There are several possible explanations. 
First, there were differences in demographic and clinical 
characteristics of patients initiating SNRIs and SSRIs. SNRI-
treated patients are more likely to be female, older, and were 
more complex (recurrent, with more severe and comorbid 
  disorders) than SSRI-treated patients.28 These patients may 
need longer therapy and better adherence. Second, SNRIs 
may have better effects than SSRIs for severe patients.22,23 
Third, SNRIs are similar to SSRIs in safety profiles.
Compared with VLX, DLX appears to have better adher-
ence and persistence. The advantage of DLX over VLX may 
share similar reasons to those for SNRIs over SSRIs and 
may be attributed to the differences in clinical and pharma-
cological profiles between the two SNRIs.24,25 DLX-treated 
patients are more complicated and have more comorbid 
conditions, especially chronic pain diseases, than VLX-
treated patients.28,39 Compared to VLX, DLX is a relatively 
balanced SNRI, displaying high affinity for both serotonin 
and norepinephrine transporters.24 In addition to MDD and 
anxiety, DLX has indications for fibromyalgia and DPNP and 
has shown efficacy for chronic low back pain.42 However, 
the differences in adherence (4%) and persistence (nine 
days) were relatively small, though they were statistically 
significant. Further research needs to examine if the small 
differences could be translated into clinically and economi-
cally meaningful outcomes.
ECP is the only branded SSRI in the United States. Our 
results show that ECP has very similar adherence and per-
sistence profiles compared to GSSRIs. This finding is not 
surprising because ECP is an SSRI and has similar clinical 
and pharmacological profiles compared to other SSRIs43 
and because ECP-treated patients are also very similar to 
GSSRI-treated patients in demographics and comorbid 
conditions.28
Consistent with previous studies,13–18,20,21 this study found 
that multiple demographical and clinical factors were asso-
ciated with adherence and persistence. For example, older 
patients were more likely to be adherent with antidepressant 
therapy. Eaddy and colleagues12 studied the   association 
between SSRI utilization patterns and use of health care 
services and reported that patients who discontinued therapy 
in the first 90 days tended to be younger. Certain comorbid 
diseases can increase or decrease the odds of discontinuation 
of antidepressant therapy. Patients with chronic headaches, 
low back pain, and alcohol and drug dependence were 
more likely to discontinue therapy, while patients with 
hypersomnia were more likely to remain adherent. Also, the 
prior use of certain medications can affect   adherence and 
persistence. Patients who have been prescribed VLX, 
ECP, anticonvulsants, and antimigraine medications have 
decreased odds of discontinuation, while patients with prior 
use of benzodiazepines, amphetamine, and opioids have 
increased odds of discontinuation. It would be warranted to 
investigate why certain comorbid disorders and medications 
are related to poor adherence and early discontinuation with 
antidepressant therapy.
Limitations
Several limitations must be considered in this retrospective 
study using a claims database. Claims database analyses 
have potential selection bias, miscoding of information 
and consequent biases in estimation. Also, adherence and 
persistence were estimated based on the presence of a claim 
for a filled prescription rather than real consumption of the 
medication as reported by patients or assessed by objective 
measures. Other limitations of this study include: the lack 
of detailed clinical data on the severity of depression, illness 
history, duration of current episode, and patient responses to 
antidepressants; and the lack of detailed social demographic 
data on education, ethnicity, employment status, income, and 
family environment; and the absence of information about 
physician and patient belief and preference. Demographic 
and clinical differences were observed between the cohorts 
of patients initiating SNRIs and SSRIs. While attempts were 
made to control for these baseline differences in measured 
variables through regression analysis, potential differences in 
the above unmeasured variables are unaccounted for – except 
in as much as they are correlated with measured variables. 
Prospective observational studies are needed to examine 
whether these findings can be generalized to the real-world 
clinical setting. In addition, although adherence and persis-
tence were statistically different across study medications, 
further research is needed to examine whether the statistical 
differences can be translated into clinically and economically 
meaningful consequences.
Conclusion
The adherence rate was 34% to 38% for SNRIs and 
approximately 25% for SSRIs in the year after initiation. 
About 30% of patients discontinued their medication within 
30 days. DLX and VLX treated patients had better adher-
ence and longer length of therapy with the medication than 
patients treated with ECP or GSSRIs. While DLX treated 
patients had statistically significantly better adherence 
and persistence than VLX, the observed differences were ClinicoEconomics and Outcomes Research 2011:3 submit your manuscript | www.dovepress.com
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relatively small and further research is needed to examine if 
these   differences translate into clinically and economically 
meaningful   outcomes. Adherence and persistence between 
ECP and GSSRIs were similar. In addition, multiple demo-
graphic and clinical factors are associated with adherence 
and persistence. Given the clinical and economic benefits of 
better adherence and persistence with antidepressant therapy, 
targeting interventions to patients who are at high risk for 
nonadherence and early discontinuation of therapy should 
be considered an important part of medication therapy for 
major depression.
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